Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt 14.39
HSKA's Cash-to-Debt is ranked higher than
61% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.04 vs. HSKA: 14.39 )
Ranked among companies with meaningful Cash-to-Debt only.
HSKA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.31  Med: 1.14 Max: No Debt
Current: 14.39
Equity-to-Asset 0.67
HSKA's Equity-to-Asset is ranked higher than
64% of the 201 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. HSKA: 0.67 )
Ranked among companies with meaningful Equity-to-Asset only.
HSKA' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.07  Med: 0.6 Max: 0.78
Current: 0.67
0.07
0.78
Interest Coverage 103.33
HSKA's Interest Coverage is ranked higher than
54% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 80.49 vs. HSKA: 103.33 )
Ranked among companies with meaningful Interest Coverage only.
HSKA' s Interest Coverage Range Over the Past 10 Years
Min: 1.89  Med: 16.29 Max: 103.33
Current: 103.33
1.89
103.33
Piotroski F-Score: 5
Altman Z-Score: 10.37
Beneish M-Score: -2.18
WACC vs ROIC
4.92%
15.26%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 12.71
HSKA's Operating Margin % is ranked higher than
75% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.12 vs. HSKA: 12.71 )
Ranked among companies with meaningful Operating Margin % only.
HSKA' s Operating Margin % Range Over the Past 10 Years
Min: -1.83  Med: 3.94 Max: 12.71
Current: 12.71
-1.83
12.71
Net Margin % 8.08
HSKA's Net Margin % is ranked higher than
74% of the 203 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.10 vs. HSKA: 8.08 )
Ranked among companies with meaningful Net Margin % only.
HSKA' s Net Margin % Range Over the Past 10 Years
Min: -1.53  Med: 2.93 Max: 42.28
Current: 8.08
-1.53
42.28
ROE % 14.14
HSKA's ROE % is ranked higher than
78% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.64 vs. HSKA: 14.14 )
Ranked among companies with meaningful ROE % only.
HSKA' s ROE % Range Over the Past 10 Years
Min: -2.49  Med: 4.84 Max: 140.27
Current: 14.14
-2.49
140.27
ROA % 8.84
HSKA's ROA % is ranked higher than
82% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.30 vs. HSKA: 8.84 )
Ranked among companies with meaningful ROA % only.
HSKA' s ROA % Range Over the Past 10 Years
Min: -1.49  Med: 3.03 Max: 61.02
Current: 8.84
-1.49
61.02
ROC (Joel Greenblatt) % 47.18
HSKA's ROC (Joel Greenblatt) % is ranked higher than
78% of the 220 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.22 vs. HSKA: 47.18 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
HSKA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -5.69  Med: 15.53 Max: 53.51
Current: 47.18
-5.69
53.51
3-Year Revenue Growth Rate 9.10
HSKA's 3-Year Revenue Growth Rate is ranked higher than
65% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. HSKA: 9.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
HSKA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -16.9  Med: 1.85 Max: 10.4
Current: 9.1
-16.9
10.4
3-Year EBITDA Growth Rate 141.70
HSKA's 3-Year EBITDA Growth Rate is ranked higher than
99% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.50 vs. HSKA: 141.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
HSKA' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -63.9  Med: -18.4 Max: 141.7
Current: 141.7
-63.9
141.7
GuruFocus has detected 3 Warning Signs with Heska Corp $HSKA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» HSKA's 10-Y Financials

Financials (Next Earnings Date: 2017-05-02)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

Latest Guru Trades with HSKA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 541940    SIC: 742
Compare:NAS:QDEL, NAS:BEAT, NAS:NEO, OTCPK:EPLYF, NAS:VIVO, NAS:NRCIA, NAS:ALOG, OTCPK:BMLIF, NYSE:ARA, NAS:KANG, NAS:PACB, NAS:NTRA, NYSE:NVTA, NAS:LNTH, NAS:NVDQ, NAS:GHDX, NAS:ABAX, NYSE:ENZ, NAS:OXFD, NAS:FMI » details
Traded in other countries:HSKN.Germany,
Headquarter Location:USA
Heska Corp is engaged in developing, manufacturing, marketing, selling and supporting veterinary products. The Company's core focus is on the canine and feline companion animal health markets.

Heska Corp was founded as Paravax, Inc. in 1988 and conducted research on vaccines to prevent infections by parasites. The Company develops, manufactures, markets, sells and supports veterinary products. The Company's core focus is on the canine and feline companion animal health markets where it provides high value products. The Company's business is comprised of two reportable segments: Core Companion Animal Health and Other Vaccines, Pharmaceuticals and Products. The Core Companion Animal Health segment includes mainly for canine and feline use, blood testing instruments and supplies as well as single use products and services such as heartworm diagnostic tests, heartworm preventive products, allergy immunotherapy products and allergy testing. These products are sold directly to veterinarians by the Company as well as through distribution relationships. The Other Vaccines, Pharmaceuticals and Products segment includes private label vaccine and pharmaceutical production, mainly for cattle but also for other animals including small mammals. All OVP products are sold by third parties under third party labels. It provides line of veterinary diagnostic and other instruments. Its line of veterinary instruments includes the following: Blood Chemistry; Hematology; Blood Gases and Electrolytes; and IV Pumps. The DRI-CHEM 4000 Veterinary Chemistry Analyzer is a robust system that uses dry slide technology for blood chemistry and electrolyte analysis and has the ability to run 22 tests at a time with a single blood sample. The HEMATRUE Veterinary Hematology Analyzer is a blood analyzer that measures such key parameters as white blood cell count, red blood cell count, platelet count and hemoglobin levels in animals. The Element POC Blood Gas & Electrolyte Analyzer is a handheld, wireless analyzer which delivers rapid blood gas, electrolyte, metabolite, and basic blood chemistry testing. EPOC features test cards with room temperature storage which can provide results with less than 100 uL of sample as well as WiFi and Bluetooth connectivity. The VET/IV 2.2 infusion pump is a compact, affordable IV pump that allows veterinarians to easily provide regulated infusion of fluids, drugs or nutritional products for their patients. Allergy is common in companion animals, and it has been estimated to affect approximately 10% to 15% of dogs. The Company sells kits to conduct blood testing using its ALLERCEPT Definitive Allergen Panels to third-party veterinary diagnostic laboratories outside of the United States. It has veterinary diagnostic laboratories in Loveland, Colorado and Fribourg, Switzerland which both provide blood testing using its ALLERCEPT Definitive Allergen Panels. Its competitors include: IDEXX Laboratories, Inc., Abaxis, Inc. and Synbiotics Corporation. The Company may be or subject to extensive regulation by governmental authorities in the United States, including the USDA and the FDA, and by similar agencies in other countries.

Ratios

vs
industry
vs
history
PE Ratio 75.89
HSKA's PE Ratio is ranked lower than
87% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.62 vs. HSKA: 75.89 )
Ranked among companies with meaningful PE Ratio only.
HSKA' s PE Ratio Range Over the Past 10 Years
Min: 0.49  Med: 34.41 Max: 604
Current: 75.89
0.49
604
Forward PE Ratio 58.14
HSKA's Forward PE Ratio is ranked lower than
93% of the 81 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.79 vs. HSKA: 58.14 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 75.89
HSKA's PE Ratio without NRI is ranked lower than
87% of the 104 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.50 vs. HSKA: 75.89 )
Ranked among companies with meaningful PE Ratio without NRI only.
HSKA' s PE Ratio without NRI Range Over the Past 10 Years
Min: 0.49  Med: 34.49 Max: 604
Current: 75.89
0.49
604
Price-to-Owner-Earnings 10859.00
HSKA's Price-to-Owner-Earnings is ranked lower than
100% of the 64 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 26.82 vs. HSKA: 10859.00 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
HSKA' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 2.83  Med: 29.76 Max: 10859
Current: 10859
2.83
10859
PB Ratio 8.77
HSKA's PB Ratio is ranked lower than
85% of the 196 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.69 vs. HSKA: 8.77 )
Ranked among companies with meaningful PB Ratio only.
HSKA' s PB Ratio Range Over the Past 10 Years
Min: 0.22  Med: 1.26 Max: 19.66
Current: 8.77
0.22
19.66
PS Ratio 6.16
HSKA's PS Ratio is ranked lower than
67% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.36 vs. HSKA: 6.16 )
Ranked among companies with meaningful PS Ratio only.
HSKA' s PS Ratio Range Over the Past 10 Years
Min: 0.12  Med: 0.77 Max: 6.17
Current: 6.16
0.12
6.17
Price-to-Free-Cash-Flow 343.64
HSKA's Price-to-Free-Cash-Flow is ranked lower than
99% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.50 vs. HSKA: 343.64 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
HSKA' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 2.44  Med: 19.43 Max: 590.34
Current: 343.64
2.44
590.34
Price-to-Operating-Cash-Flow 139.38
HSKA's Price-to-Operating-Cash-Flow is ranked lower than
99% of the 86 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.60 vs. HSKA: 139.38 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
HSKA' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 2.36  Med: 23.67 Max: 280.59
Current: 139.38
2.36
280.59
EV-to-EBIT 45.41
HSKA's EV-to-EBIT is ranked lower than
85% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.08 vs. HSKA: 45.41 )
Ranked among companies with meaningful EV-to-EBIT only.
HSKA' s EV-to-EBIT Range Over the Past 10 Years
Min: -111.6  Med: 22.1 Max: 172
Current: 45.41
-111.6
172
EV-to-EBITDA 35.54
HSKA's EV-to-EBITDA is ranked lower than
87% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.34 vs. HSKA: 35.54 )
Ranked among companies with meaningful EV-to-EBITDA only.
HSKA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -43  Med: 12.6 Max: 59.1
Current: 35.54
-43
59.1
PEG Ratio 2.38
HSKA's PEG Ratio is ranked higher than
65% of the 43 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.96 vs. HSKA: 2.38 )
Ranked among companies with meaningful PEG Ratio only.
HSKA' s PEG Ratio Range Over the Past 10 Years
Min: 2.38  Med: 51.7 Max: 65.79
Current: 2.38
2.38
65.79
Shiller PE Ratio 99.38
HSKA's Shiller PE Ratio is ranked lower than
87% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 39.15 vs. HSKA: 99.38 )
Ranked among companies with meaningful Shiller PE Ratio only.
HSKA' s Shiller PE Ratio Range Over the Past 10 Years
Min: 7.39  Med: 22.58 Max: 339.33
Current: 99.38
7.39
339.33
Current Ratio 1.71
HSKA's Current Ratio is ranked lower than
68% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. HSKA: 1.71 )
Ranked among companies with meaningful Current Ratio only.
HSKA' s Current Ratio Range Over the Past 10 Years
Min: 1.22  Med: 2.02 Max: 5.51
Current: 1.71
1.22
5.51
Quick Ratio 1.08
HSKA's Quick Ratio is ranked lower than
80% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. HSKA: 1.08 )
Ranked among companies with meaningful Quick Ratio only.
HSKA' s Quick Ratio Range Over the Past 10 Years
Min: 0.72  Med: 1.21 Max: 4.68
Current: 1.08
0.72
4.68
Days Inventory 89.07
HSKA's Days Inventory is ranked lower than
52% of the 171 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 79.87 vs. HSKA: 89.07 )
Ranked among companies with meaningful Days Inventory only.
HSKA' s Days Inventory Range Over the Past 10 Years
Min: 82.09  Med: 106.38 Max: 109.49
Current: 89.07
82.09
109.49
Days Sales Outstanding 58.52
HSKA's Days Sales Outstanding is ranked higher than
55% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 62.33 vs. HSKA: 58.52 )
Ranked among companies with meaningful Days Sales Outstanding only.
HSKA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 41.35  Med: 49.25 Max: 58.52
Current: 58.52
41.35
58.52
Days Payable 34.27
HSKA's Days Payable is ranked lower than
68% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 53.45 vs. HSKA: 34.27 )
Ranked among companies with meaningful Days Payable only.
HSKA' s Days Payable Range Over the Past 10 Years
Min: 26.98  Med: 34.99 Max: 46.37
Current: 34.27
26.98
46.37

Buy Back

vs
industry
vs
history
5-Year Yield-on-Cost % 0.90
HSKA's 5-Year Yield-on-Cost % is ranked lower than
68% of the 106 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.33 vs. HSKA: 0.90 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
HSKA' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.79  Med: 2.22 Max: 3.73
Current: 0.9
0.79
3.73
3-Year Average Share Buyback Ratio -6.30
HSKA's 3-Year Average Share Buyback Ratio is ranked lower than
51% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.00 vs. HSKA: -6.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
HSKA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -38.6  Med: -2.75 Max: -0.4
Current: -6.3
-38.6
-0.4

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 67.03
HSKA's Price-to-Net-Current-Asset-Value is ranked lower than
95% of the 122 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.79 vs. HSKA: 67.03 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
HSKA' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.47  Med: 3.11 Max: 67.03
Current: 67.03
2.47
67.03
Price-to-Tangible-Book 13.16
HSKA's Price-to-Tangible-Book is ranked lower than
77% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.28 vs. HSKA: 13.16 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
HSKA' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.31  Med: 2.24 Max: 131.35
Current: 13.16
0.31
131.35
Price-to-Intrinsic-Value-Projected-FCF 11.11
HSKA's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
87% of the 70 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.10 vs. HSKA: 11.11 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
HSKA' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.6  Med: 0.91 Max: 20.8
Current: 11.11
0.6
20.8
Price-to-Median-PS-Value 7.99
HSKA's Price-to-Median-PS-Value is ranked lower than
99% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. HSKA: 7.99 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
HSKA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.21  Med: 1.18 Max: 9.72
Current: 7.99
0.21
9.72
Price-to-Graham-Number 6.67
HSKA's Price-to-Graham-Number is ranked lower than
89% of the 61 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.97 vs. HSKA: 6.67 )
Ranked among companies with meaningful Price-to-Graham-Number only.
HSKA' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.54  Med: 2.66 Max: 19.7
Current: 6.67
0.54
19.7
Earnings Yield (Greenblatt) % 2.23
HSKA's Earnings Yield (Greenblatt) % is ranked lower than
51% of the 297 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.45 vs. HSKA: 2.23 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
HSKA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.6  Med: 4 Max: 21.2
Current: 2.23
0.6
21.2
Forward Rate of Return (Yacktman) % -2.95
HSKA's Forward Rate of Return (Yacktman) % is ranked lower than
80% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.75 vs. HSKA: -2.95 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
HSKA' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -15.3  Med: -2 Max: 7.5
Current: -2.95
-15.3
7.5

More Statistics

Revenue (TTM) (Mil) $130.1
EPS (TTM) $ 1.43
Beta0.45
Short Percentage of Float1.58%
52-Week Range $26.26 - 109.10
Shares Outstanding (Mil)7.08

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 151 173 180
EPS ($) 1.86 2.33 2.55
EPS without NRI ($) 1.86 2.33 2.55
EPS Growth Rate
(Future 3Y To 5Y Estimate)
17.80%
Dividends per Share ($)
» More Articles for HSKA

Headlines

Articles On GuruFocus.com
Reminder: Heska Annual Meeting of Stockholders on May 1, 2017 Apr 25 2017 
Heska Schedules First Quarter 2017 Financial Results Conference Call for May 2, 2017 Apr 13 2017 
Heska Schedules Annual Meeting of Stockholders for May 1, 2017 Apr 12 2017 
Gartner Set to Join S&P 500; Dun & Bradstreet, Wintrust Financial and INC Research to Join S&P MidCa Mar 31 2017 
'Kittens Equal Happiness': GAMCO Analyst on Zoetis, Heska, Smuckers Oct 07 2016 
Heska's Still has Room to Run Aug 19 2016 
My 5 Favorite High Beta Health Care Dividend Stocks Aug 02 2013 
20 Best Yielding Healthcare Growth Stocks and Which to Buy Feb 02 2013 
Heska Corporation: Strong Balance Sheet and Dividend Yield Do Not Compensate for Difficult Business Dec 13 2012 
Weekly CFO Buys Highlight: Apollo Investment Corp., Dyax Corp., Heska Corp., Vaughan Foods Inc., Wir Jun 05 2010 

More From Other Websites
Medical Device Maker Bolts Higher On Earnings In Massive Volume Apr 26 2017
Reminder: Heska Annual Meeting of Stockholders on May 1, 2017 Apr 25 2017
CytRx Gets Clarity from FDA for Aldoxorubicin NDA, Shares Up Apr 20 2017
Zacks.com featured highlights: Heska, Zeltiq Aesthetics, YY, MaxLinear and Teradyne Apr 20 2017
Ultragenyx's Hypophosphatemia Drug Succeeds in Phase III Apr 19 2017
Create an Efficient Portfolio with 5 Top Stocks Apr 19 2017
Bristol-Myers and Nordic Ink Biomarker Collaboration Deal Apr 18 2017
Rigel Pharmaceuticals Files NDA for Thrombocytopenia Drug Apr 18 2017
Eli Lilly's Rheumatoid Arthritis Drug Gets CRL in the U.S. Apr 17 2017
Illumina (ILMN) Launches VeriSeq NIPT Solution in Europe Apr 13 2017
Heska Schedules First Quarter 2017 Financial Results Conference Call for May 2, 2017 Apr 13 2017
Heska Schedules Annual Meeting of Stockholders for May 1, 2017 Apr 12 2017
Gilead (GILD) HCV Drugs Gets FDA Nod for Label Expansion Apr 10 2017
Roche's Lung Cancer Drug Alecensa Meets Primary Endpoint Apr 10 2017
Bristol-Myers' (BMY) sBLA For Opdivo Accepted by the FDA Apr 06 2017
Today's Strong Buy Stocks at New Highs Apr 05 2017
Celgene (CELG) Gets Paragraph IV Notice Letter for Pomalyst Apr 05 2017
Roche Announces Positive Data on Lung Cancer Drug Alecensa Apr 05 2017
Amedisys (AMED) Poised on Strong Home Health, Risks Remain Apr 05 2017
Bristol-Myers Announces Data on Immuno-oncology Drug Opdivo Apr 04 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)